Evidence map›Paper›PMID 35972545›Full record

ArticleParasitology research2022

In vitro interaction of polyethylene glycol-block-poly(D,L-lactide) nanocapsule devices with host cardiomyoblasts and Trypanosoma cruzi-infective forms.

Raoni Pais Siqueira, Matheus Marques Milagre, Maria Alice de Oliveira, Renata Tupinambá Branquinho, Fernanda Karoline Vieira Torchelsen, Marta de Lana, Marina Guimarães Carvalho Machado, Margareth Spangler Andrade, Maria Terezinha Bahia, Vanessa Carla Furtado Mosqueira

Abstract read
PubMed Publisher
In one paragraph

Article in Parasitology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Albaconazole Polymeric Nanocapsules for TreatingPathogens (Basel, Switzerland) · 2025
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Raoni Pais SiqueiraLaboratory of Pharmaceutics and Nanotechnology (LDGNano), School of Pharmacy, Federal University of Ouro Preto, Campus Universitário Morro do Cruzeiro, Ouro Preto, MG, 35400-000, Brazil. raoni.siqueira1@gmail.com.ORCID http://orcid.org/0000-0003-3015-1187
Matheus Marques MilagrePost-graduation Program in Pharmaceutical Sciences - School of Pharmacy, Federal University of Ouro Preto, Ouro Preto, MG, Brazil.
Maria Alice de OliveiraLaboratory of Pharmaceutics and Nanotechnology (LDGNano), School of Pharmacy, Federal University of Ouro Preto, Campus Universitário Morro do Cruzeiro, Ouro Preto, MG, 35400-000, Brazil.
Renata Tupinambá BranquinhoPost-graduation Program in Pharmaceutical Sciences - School of Pharmacy, Federal University of Ouro Preto, Ouro Preto, MG, Brazil.
Fernanda Karoline Vieira TorchelsenPost-graduation Program in Pharmaceutical Sciences - School of Pharmacy, Federal University of Ouro Preto, Ouro Preto, MG, Brazil.
Marta de LanaPost-graduation Program in Pharmaceutical Sciences - School of Pharmacy, Federal University of Ouro Preto, Ouro Preto, MG, Brazil.
Marina Guimarães Carvalho MachadoLaboratory of Pharmaceutics and Nanotechnology (LDGNano), School of Pharmacy, Federal University of Ouro Preto, Campus Universitário Morro do Cruzeiro, Ouro Preto, MG, 35400-000, Brazil.
Margareth Spangler AndradeNanoscopy Laboratory - Technological Center (Cetec-SENAI), Belo Horizonte, MG, Brazil.
Maria Terezinha BahiaLaboratory of Parasitic Diseases - NUPEB, Medical School, Federal University of Ouro Preto, Ouro Preto, MG, Brazil.
Vanessa Carla Furtado MosqueiraLaboratory of Pharmaceutics and Nanotechnology (LDGNano), School of Pharmacy, Federal University of Ouro Preto, Campus Universitário Morro do Cruzeiro, Ouro Preto, MG, 35400-000, Brazil. mosqueira@ufop.edu.br.ORCID http://orcid.org/0000-0002-0368-6090
Universidade Federal de Ouro Preto · BRServiço Nacional de Aprendizagem Industrial · BR

Funding

BRICS-STI #442351/2017-8Conselho Nacional de Desenvolvimento Científico e Tecnológico #313602/2019-0Conselho Nacional de Desenvolvimento Científico e Tecnológico #400889/2014-5Conselho Nacional de Desenvolvimento Científico e Tecnológico #465687/2014-8
6 · The paper itself

Abstract

Chagas disease, caused by the protozoan Trypanosoma cruzi, is an important public health problem in Latin America. Nanoencapsulation of anti-T. cruzi drugs has significantly improved their efficacy and reduced cardiotoxicity. Thus, we investigated the in vitro interaction of polyethylene glycol-block-poly(D,L-lactide) nanocapsules (PEG-PLA) with trypomastigotes and with intracellular amastigotes of the Y strain in cardiomyoblasts, which are the infective forms of T. cruzi, using fluorescence and confocal microscopy. Fluorescently labeled nanocapsules (NCs) were internalized by non-infected H9c2 cells toward the perinuclear region. The NCs did not induce significant cytotoxicity in the H9c2 cells, even at the highest concentrations and interacted equally with infected and non-infected cells. In infected cardiomyocytes, NCs were distributed in the cytoplasm and located near intracellular amastigote forms. PEG-PLA NCs and trypomastigote form interactions also occurred. Altogether, this study contributes to the development of engineered polymeric nanocarriers as a platform to encapsulate drugs and to improve their uptake by different intra- and extracellular forms of T. cruzi, paving the way to find new therapeutic strategies to fight the causative agent of Chagas disease.

Indexed as

Chagas DiseaseNanocapsulesTrypanosoma cruziHumansPolyestersPolyethylene GlycolsNanocapsulesPolyestersPolyethylene Glycolspoly(lactide)CardiomyoblastCell uptakeNanocapsulesPolyethylene glycol-block-poly(D,L-lactide)Trypanosoma cruzi

Identifiers

PMID35972545
OpenAlexW4292183888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.